labetalol has been researched along with Thyrotoxicosis in 1 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Thyrotoxicosis: A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING.
Excerpt | Relevance | Reference |
---|---|---|
"Fetal tachycardia was present as well." | 5.30 | Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis. ( Bergmann, M; Bowman, ML; Smith, JF, 1998) |
"Fetal tachycardia was present as well." | 1.30 | Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis. ( Bergmann, M; Bowman, ML; Smith, JF, 1998) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bowman, ML | 1 |
Bergmann, M | 1 |
Smith, JF | 1 |
1 other study available for labetalol and Thyrotoxicosis
Article | Year |
---|---|
Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis.
Topics: Adolescent; Female; Fetal Diseases; Heart Rate, Fetal; Humans; Hypertension; Infant, Newborn; Infant | 1998 |